^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Guanylate cyclase stimulant

    Related drugs:
    1d
    Chuanxiong Qingnao Granules (CQG) alleviates nitroglycerin-induced migraine-like pain in rats by glycerophospholipid metabolism and PI3K/Akt signaling pathway. (PubMed, Phytomedicine)
    Taken together, CQG inhibited PI3K/Akt signaling pathway to reduced neuroinflammation, and modulated metabolic pathway of glycerophospholipid metabolism in MH. The findings of this study offer novel insights into the mechanisms underlying the therapeutic effects of CQG, highlighting its potential clinical application in treatment of MH.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • CALCRL (Calcitonin Receptor Like Receptor)
    |
    nitroglycerin
    7d
    ROAR: A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, Bayer | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • Real-world evidence • Real-world
    19d
    Inhaled Nitric Oxide in Severe Obesity (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Massachusetts General Hospital | Phase classification: P2 --> P=N/A
    Phase classification
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    19d
    S2R: Sildenafil Switching to Riociguat (clinicaltrials.gov)
    P4, N=30, Recruiting, Chinese University of Hong Kong
    New P4 trial
    |
    sildenafil
    25d
    Nephroprotective effects of the soluble guanylyl cyclase stimulator, riociguat in doxorubicin-induced acute kidney injury in rats. (PubMed, Toxicol Rep)
    Concomitant treatment with riociguat ameliorated these DX-induced changes with parallel histopathological improvements but the effects were more favorable with high-dose riociguat. The observed renoprotective effects of riociguat can be partly attributed to the anti-inflammatory and anti-oxidant properties of this drug.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • LCN2 (Lipocalin-2) • IL1B (Interleukin 1, beta) • CAT (Catalase)
    |
    doxorubicin hydrochloride
    28d
    NORISC: Nitric Oxide for Reduced Intensive Support in Cardiac Surgery with Cardiopulmonary Bypass (clinicaltrials.gov)
    P3, N=3650, Not yet recruiting, Xijing Hospital
    New P3 trial • Adverse events • Surgery
    1m
    EPIPHANY: Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH (clinicaltrials.gov)
    P3, N=15, Not yet recruiting, Dr Sudarshan Rajagopal | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    1m
    Preventing radial artery spasm during cerebral angiography via transradial access by intra-arterial administration of spasmolytic and using The Glidesheath Slender Sheath (ChiCTR2400089250)
    P=N/A, N=248, Not yet recruiting, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tec
    New trial
    |
    nitroglycerin
    2ms
    Inhaled Nitric Oxide in Severe Obesity (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    3ms
    Clinical study on the treatment of stable angina pectoris (Qi deficiency and blood stasis syndrome) with yellow black tea Shengmai decoction (ChiCTR2400086983)
    P4, N=86, Not yet recruiting, The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine
    New P4 trial
    |
    nitroglycerin
    3ms
    The Effect of Nebulizied Nitroglycerin As an Adjuvant Therapy for Persistent Pulmonary Hypertension of Newborns (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Alexandria University | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    nitroglycerin
    3ms
    POINT-NOCAD: PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease (clinicaltrials.gov)
    P=N/A, N=32, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting | N=100 --> 32
    Enrollment closed • Enrollment change
    |
    nitroglycerin
    4ms
    PATENT-CHILD: Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov)
    P3, N=24, Active, not recruiting, Bayer | Trial completion date: Jan 2031 --> Jul 2026
    Trial completion date
    |
    CA6 (Carbonic Anhydrase 6)
    4ms
    A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Beyond Air Inc. | Trial completion date: Apr 2025 --> Jun 2025 | Trial primary completion date: Jul 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    ultra-high concentration nitric oxide (UNO101)
    5ms
    Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Vanderbilt University | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    nitroglycerin
    5ms
    Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia (clinicaltrials.gov)
    P1/2, N=182, Terminated, AdventHealth | Trial completion date: Dec 2024 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Oct 2023; based on DSMB recommendation at interim analysis
    Trial completion date • Trial termination • Trial primary completion date
    5ms
    Comparison Between Loupe-Assisted Varicocelectomy With Nitroglycerin Instillation and Microscopic Varicocelectomy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Fayoum University Hospital
    New trial
    |
    nitroglycerin
    5ms
    A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) (clinicaltrials.gov)
    P2/3, N=168, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    5ms
    Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia (clinicaltrials.gov)
    P1/2, N=182, Active, not recruiting, AdventHealth | Recruiting --> Active, not recruiting | N=138 --> 182
    Enrollment closed • Enrollment change
    5ms
    Effect of Riocigaut on Migraine Attack Induction in People With Migraine (clinicaltrials.gov)
    P=N/A, N=22, Completed, Danish Headache Center | Not yet recruiting --> Completed | Trial completion date: May 2024 --> Feb 2024 | Trial primary completion date: May 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    6ms
    EPIPHANY: Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH (clinicaltrials.gov)
    P3, N=15, Not yet recruiting, Dr Sudarshan Rajagopal | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    6ms
    Methemoglobin Concentration in High Dose Inhaled Nitric Oxide (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    7ms
    Understanding the Pathophysiology of Migraine Pain (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Montefiore Medical Center | Suspended --> Recruiting | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    nitroglycerin
    7ms
    Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    7ms
    Understanding the Pathophysiology of Migraine Pain (clinicaltrials.gov)
    P=N/A, N=10, Suspended, Montefiore Medical Center | N=20 --> 10
    Enrollment change
    |
    nitroglycerin
    8ms
    NEXT: Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis (clinicaltrials.gov)
    P1, N=25, Recruiting, University Hospital, Basel, Switzerland | Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    nitroglycerin
    8ms
    A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) (clinicaltrials.gov)
    P2/3, N=168, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | N=450 --> 168 | Trial completion date: Jan 2028 --> Aug 2024 | Trial primary completion date: Feb 2026 --> Jan 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    8ms
    Guanylate cyclase 2C (GUCY2C; GUC) expression and the tumor immune microenvironment (TIME) in gastrointestinal (GI) cancers. (ASCO 2024)
    GUC is expressed across GI cancers and GUC-H tumors are characterized by an "immune cold" TIME but longer OS. These results should be taken into consideration while evaluating the clinical utility of GUC as a novel immunotherapy target in advanced GI cancers that historically have not responded to ICI.
    PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • GUCY2C (Guanylate Cyclase 2C)
    |
    PD-L1 IHC 22C3 pharmDx
    9ms
    A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Beyond Air Inc. | Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ultra-high concentration nitric oxide (UNO101)
    9ms
    Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock. (clinicaltrials.gov)
    P=N/A, N=44, Completed, University of Pennsylvania | N=25 --> 44
    Enrollment change
    |
    nitroglycerin
    9ms
    iNO: Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    9ms
    Vascular ARDS Recruitment After Inhaled Nitric Oxide (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    VEGFA (Vascular endothelial growth factor A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10)
    9ms
    ESRA: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH (clinicaltrials.gov)
    P2, N=70, Recruiting, Heidelberg University | Phase classification: P2a --> P2
    Phase classification
    10ms
    Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 (clinicaltrials.gov)
    P4, N=32, Active, not recruiting, Vanderbilt University Medical Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    10ms
    Topical Nitro or Placebo Pre-Cath (clinicaltrials.gov)
    P2, N=256, Not yet recruiting, Thomas Jefferson University
    New P2 trial
    |
    nitroglycerin
    10ms
    MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD (clinicaltrials.gov)
    P2, N=120, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2026 --> Mar 2028 | Trial primary completion date: Mar 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    10ms
    AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Kaohsiung Medical University Chung-Ho Memorial Hospital
    New trial • Surgery
    |
    nitroglycerin
    10ms
    Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. (clinicaltrials.gov)
    P=N/A, N=74, Recruiting, Instituto Nacional de Cancerologia de Mexico
    New trial
    |
    nitroglycerin
    11ms
    Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Yuri Matusov
    New P1 trial
    11ms
    The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Alexandria University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    nitroglycerin
    11ms
    ROAR: A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence • Real-world
    11ms
    JPMS-CTEPH: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (clinicaltrials.gov)
    P=N/A, N=1298, Completed, Bayer | Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Aug 2023
    Trial completion • Trial completion date